Esta página foi traduzida automaticamente. Se houver alguma discrepância, a versão em inglês é a autêntica.

CuringHeartDisease

Sempre em busca de uma cura
Peter Megdal, PhD
Junte-se à Nossa Causa

Qual deve ser o nível do colesterol LDL após um ataque cardíaco?

Por: Peter Megdal PhD

Como Usar Este Artigo

Escolha o seu formato
Texto Fácil
Mergulho profundo
YouTube
Spotify
Apresentação de slides
  • Com base em pesquisas médicas revisadas por pares
  • As mesmas evidências que os cardiologistas usam
  • Escrito em linguagem clara para o público
  • Procure por termos sublinhados e links relacionados

Aviso médico: Este artigo é apenas para fins educativos e não constitui aconselhamento médico. Consulte sempre o seu médico para obter orientação pessoal.

Conclusões clínicas

  • A redução intensiva do colesterol LDL estabiliza as placas coronárias vulneráveis, aumentando a espessura das capas fibrosas protetoras e reduzindo o conteúdo lipídico, com alterações modestas no volume.
  • A redução substancial do colesterol LDL diminui a recorrência de ataques cardíacos e acidentes vasculares cerebrais isquêmicos, embora o risco de eventos cardiovasculares nunca caia completamente a zero.
  • As diretrizes atuais recomendam atingir um nível de colesterol LDL inferior a 55 mg/dL para pacientes com risco muito elevado após um evento cardiovascular.

Texto Fácil

A grande ideia em um minuto

  • Muito baixo LDL pode melhorar placa características associadas a um menor risco de ruptura. No Huygens De acordo com o estudo, pessoas que haviam acabado de sofrer um infarto sem elevação do segmento ST ataque cardíaco (NSTEMI) e conduziram seu Colesterol LDL quem apresentou redução para cerca de 28 mg/dL apresentou um aumento na espessura mínima da capa fibrosa aproximadamente duas vezes maior do que as pessoas em um estatina por si só. Isso compara a magnitude dos aumentos, e não os limites em si, e não comprova uma redução correspondente no risco de ataque cardíaco [1].
  • Por outro lado, a redução do LDL previne ataques cardíacos e derrames. O estudo HUYGENS avaliou a placa aterósclerótica, e não os ataques cardíacos. As evidências de que níveis mais baixos de LDL previnem eventos provêm de diferentes ensaios clínicos randomizados, muito maiores, envolvendo dezenas de milhares de pessoas, que demonstraram uma redução no número de novos ataques cardíacos, acidentes vasculares cerebrais e procedimentos cardíacos [2, 3, 4].
  • Tanto a intensidade quanto a duração da redução do LDL são importantes. Estudos genéticos sugerem que níveis mais baixos de LDL ao longo da vida colesterol está associado a uma proteção cumulativa substancialmente maior contra doença cardíaca coronariana [5, 6].
  • A redução do LDL tem sido acompanhada por uma diminuição no número de eventos, mas o risco nunca chega a zero. Os estudos analisados não identificaram um limite mínimo claro para o benefício, mas as evidências tornam-se escassas em níveis extremamente baixos. Os ataques cardíacos e os derrames continuam ocorrendo mesmo com níveis muito baixos de LDL.

Figura 1. Níveis ilustrativos de colesterol LDL relatados em três ensaios clínicos diferentes com inibidores da PCSK9, cada um no grupo que tomou o medicamento. Apenas os valores durante o tratamento são apresentados, pois os ensaios relataram seus valores iniciais de maneiras diferentes, que não permitem uma comparação lado a lado. Essas não são comparações diretas entre os tratamentos e não representam o efeito adicional em relação a placebo; parte da redução do LDL em cada grupo foi atribuída à estatina. Os valores são apresentados de forma diferente: HUYGENS e PACMAN-AMI relatório significa, Fourier uma mediana [1, 7, 2].

Por que um ataque cardíaco costuma levar a outro

Muitas pessoas que sofrem um ataque cardíaco são submetidas a um raio-X das artérias do coração e, quando necessário, têm a artéria obstruída artéria é realizada com um balão e um pequeno tubo de malha chamado stent; o tratamento depende do tipo de infarto e das artérias afetadas. Um stent trata um único ponto. Mas as artérias do coração geralmente apresentam muitas outras áreas com acúmulo de placas, chamadas placa. Muitas delas parecem pequenas em uma radiografia das artérias, mas é nelas que se origina grande parte dos futuros ataques cardíacos.

No Estudo PROSPECT de 697 pessoas acompanhadas por três anos após um ataque cardíaco ou angina instável, cerca de 1 em cada 5 sofreu um evento cardíaco grave. Esse número inclui mortes relacionadas ao coração, parada cardíaca, ataque cardíaco e internações hospitalares devido ao agravamento da dor no peito; portanto, isso não significa que 1 em cada 5 tenha outro ataque cardíaco, e alguns eventos posteriores decorreram de placas não tratadas anteriormente que, no início, pareciam apresentar apenas um estreitamento leve [8]. Portanto, o verdadeiro objetivo após um ataque cardíaco não é apenas corrigir o local obstruído. É fazer com que todos as outras placas, menos perigosas.

Como é uma placa bacteriana perigosa

Uma placa se encontra no interior da parede da artéria. No seu centro, há uma acumulação macia e gordurosa de colesterol. Por cima dela, há uma camada protetora de tecido resistente chamada cápula fibrosa.

Figura 2. Como ocorre um ataque cardíaco (esquema, sem escala). Uma placa com uma camada externa espessa e um pequeno núcleo lipídico é relativamente estável (painel 1). Uma placa com uma camada fina sobre um grande núcleo lipídico é frágil (painel 2). Se a camada se romper, o sangue entra em contato com o núcleo lipídico e forma-se um coágulo que pode obstruir a artéria (painel 3). Na erosão (painel 4), a camada fibrosa permanece intacta; o revestimento interno da artéria (endotélio) se perde e se forma um coágulo na superfície exposta. Nenhum exame pode prever se uma determinada placa irá se romper.

As placas mais perigosas têm um capa fina estendido sobre um grande, macio, com o miolo gorduroso. Quando uma fina camada se rompe, o sangue entra em contato com o núcleo gorduroso e pode se formar um coágulo. Se o coágulo bloquear o fluxo sanguíneo por tempo suficiente, pode causar um ataque cardíaco. Erosão da placa e outros mecanismos também podem causar isso. Uma tampa mais grossa pode ser mais difícil de rasgar, embora a espessura por si só não seja garantia.

Como o colesterol penetra na parede arterial

O colesterol não consegue circular pelo sangue por conta própria. Ele viaja dentro de minúsculas partículas, como passageiros em carros. Essas partículas penetram na parede da artéria, ficam presas ali e, aos poucos, formam a placa. Seu Colesterol LDL Esse número indica a quantidade de colesterol que as partículas transportam. Outro exame, ApoB, é um indicador útil da concentração dessas partículas, pois cada partícula principal transportadora de colesterol carrega uma molécula de ApoB; o exame mede a concentração de ApoB, portanto, estima o número de partículas em vez de contá-las literalmente.

Figura 3. Ilustração conceitual. O colesterol é transportado por partículas, e são essas partículas que penetram na parede arterial. Duas pessoas podem ter o mesmo nível de colesterol LDL, mas números diferentes de partículas. A ApoB estima o número dessas partículas porque cada uma delas, normalmente, carrega uma molécula de ApoB; pense nisso como contar os carros, enquanto o colesterol LDL mede a carga deles. Nem todas as partículas reais penetram na parede da mesma forma, e os remanescentes do intestino transportam uma forma mais curta chamada ApoB-48; o desenho simplifica isso.

Por que isso é importante para você. Se você tiver um nível elevado de triglicerídeos, diabetes, ou excesso de peso, seu colesterol LDL pode parecer normal, embora o número de partículas ainda esteja alto. Pergunte ao seu médico se faz sentido você fazer um exame de ApoB.

O Estudo HUYGENS: Um olhar ao interior das artérias

Um cateter de imagem de alta resolução que utiliza luz, chamado OUT, permite medir a capa fibrosa em pacientes vivos. Os médicos a inserem nas artérias do coração. Ela é afiada o suficiente para medir uma capa mais fina do que um fio de cabelo humano.

O estudo HUYGENS utilizou essa câmera. Ele incluiu 161 pessoas que haviam acabado de sofrer um infarto do miocárdio sem elevação do segmento ST (NSTEMI) e que apresentavam placas de aparência frágil em outra artéria. Todos tomavam uma estatina. Metade deles também tomava evolocumabe, uma injeção que reduz ainda mais o colesterol LDL, enquanto a outra metade recebeu uma injeção de placebo. Após cerca de um ano, os médicos realizaram novos exames de imagem nos mesmos segmentos da artéria. Os resultados referem-se a esses segmentos medidos, e não a todas as placas presentes no coração [9, 1].

Estatina mais placebo Estatina mais evolocumabe
Colesterol LDL após o tratamento Cerca de 87 mg/dL Cerca de 28 mg/dL
Alteração na tampa protetora Espessura de cerca de 22 micrômetros Espessura de aproximadamente 43 micrômetros
Sinal de placa gordurosa na OCT (arco lipídico) Encolheu Encolheu ainda mais
Tamanho total da placa (ultrassom, em um subconjunto; exploratório) Quase não mudou Encolheu um pouco

Figura 4. Os aumentos médios na parte mais fina da capa fibrosa foram de 21,5 micrômetros com o uso isolado de estatina, contra 42,7 com a adição de evolocumabe (P = 0,015). Essas barras mostram a variação, e não a espessura final da capa. Trata-se de estimativas do modelo para todos os 161 pacientes tratados, dos quais 119 apresentavam imagens de OCT emparelhadas. Um micrômetro equivale a um milésimo de milímetro. Essas alterações nas imagens não foram validadas como um indicador de redução no número de ataques cardíacos para nenhum paciente individualmente [1].

Um segundo estudo, PACMAN-AMI, iniciaram o tratamento com um medicamento semelhante dentro de 24 horas após um ataque cardíaco e utilizaram três técnicas de imagem diferentes, cada uma medindo um parâmetro distinto: o ultrassom mediu o tamanho da placa, um exame químico baseado em luz mediu o sinal de gordura e a OCT mediu a camada de cobertura. Em conjunto, esses exames revelaram placas ligeiramente menores, um sinal de gordura mais baixo e camadas de cobertura mais espessas [7].

A lição principal. O colesterol LDL muito baixo mudou de que material é feita a placa muito mais do que qual é o tamanho disso. A placa não desapareceu, mas suas características de imagem passaram a se assemelhar às associadas a um menor risco de ruptura. Ainda não foi comprovado se essas mudanças são o que previne os ataques cardíacos.

Isso realmente previne ataques cardíacos?

Uma placa aterosclerótica com melhor aparência é animadora, mas o que importa para as pessoas é a redução do número de ataques cardíacos, derrames e mortes. Para isso, analisamos estudos muito mais amplos que acompanharam dezenas de milhares de pessoas.

A resposta é sim. No estudo FOURIER, que envolveu mais de 27.000 pessoas com doenças cardíacas, a adição de evolocumabe a uma estatina reduziu o risco do desfecho primário composto do estudo, que incluiu morte cardiovascular, infarto do miocárdio, acidente vascular cerebral e hospitalização por instabilidade angina, ou um procedimento de desobstrução de artérias em cerca de 15% ao longo de aproximadamente dois anos [2]. Em termos absolutos, isso representou cerca de 1,5 pessoa a menos a cada 100. Os ataques cardíacos diminuíram em cerca de um quarto, e os derrames, em cerca de um quinto. Estudos semelhantes com outros medicamentos para redução do colesterol observaram o mesmo padrão [3, 4, 10].

Figura 5. O que significa “risco menor de 15%” na prática. De cada 1.000 pessoas que tomaram apenas uma estatina, cerca de 113 tiveram um evento grave ao longo de aproximadamente dois anos; com a adição do evolocumab, esse número caiu para cerca de 98, ou seja, cerca de 15 a menos por 1.000. O 15% representa uma redução relativa do risco; os 15 por 1.000 são a diferença absoluta, um número distinto. Ambos são valores aproximados, baseados nas taxas estimadas de eventos do estudo em uma mediana de 2,2 anos, e a contagem de “eventos graves” inclui internações por dor no peito e procedimentos de desobstrução arterial, não apenas ataques cardíacos [2].

O efeito parece ainda maior quando se leva em conta todos os eventos, e não apenas o primeiro. Muitas pessoas que sofrem um ataque cardíaco ou um AVC acabam tendo outro. Quando o estudo FOURIER contabilizou todos eles, uma análise pré-especificada do total de eventos estimou aproximadamente 52 eventos a menos no desfecho primário a cada 1.000 pacientes ao longo de três anos, incluindo eventos repetidos [11].

Figura 6. Estimativa de eventos evitados por 1.000 pessoas ao longo de três anos, considerando apenas os primeiros eventos versus incluir também os eventos repetidos. Trata-se de estimativas provenientes de uma análise pré-especificada de eventos totais do estudo FOURIER, e não de contagens brutas de pacientes; além disso, os dois métodos de contagem não são diretamente comparáveis; o número maior não significa que o risco relativo a redução dobrou [11].

Uma análise histórica que reuniu dados individuais de pacientes de 26 ensaios clínicos com estatinas e cerca de 170.000 pessoas constatou que cada redução de 38,7 mg/dL (1 mmol/L) no colesterol LDL diminuía os eventos cardíacos graves e os acidentes vasculares cerebrais em cerca de 22%, além de reduzir também o número de mortes [12]. A magnitude da redução do LDL e a duração desse efeito são os principais fatores determinantes do benefício, embora os medicamentos difiram quanto ao nível de evidência que os sustenta, ao momento em que atuam e aos seus efeitos colaterais [13].

O tempo é o ingrediente secreto

Quanto mais tempo o colesterol LDL permanecer baixo, maiores serão os benefícios acumulados.

No estudo FOURIER, o benefício foi maior após o primeiro ano do que durante o próprio ano [2]. Após o término do estudo, todos os sobreviventes que optaram por continuar receberam evolocumab por mais cerca de cinco anos. As pessoas que haviam iniciado o tratamento dois anos antes ainda apresentaram menos ataques cardíacos, acidentes vasculares cerebrais e mortes relacionadas ao coração, embora ambos os grupos estivessem agora tomando o mesmo medicamento [14]. Essa comparação posterior não foi cega e incluiu apenas pessoas que optaram por continuar o tratamento; portanto, trata-se de evidência de apoio, e não de prova; ela é compatível com a ideia de que um início mais precoce traz uma vantagem duradoura, mas não a comprova.

Figura 7. Trajetórias ilustrativas do colesterol LDL ao longo da vida; não se trata de dados medidos. As idades, os níveis iniciais e as curvas são hipotéticos. Exposição cumulativa é a área sob cada curva: o tratamento após um infarto reduz a exposição futura, mas não consegue apagar décadas de exposição passada, enquanto pessoas nascidas com baixo nível de colesterol LDL acumulam muito menos. A queda acentuada aos 55 anos é conceitual, não uma trajetória clínica medida, e a área sob uma curva, por si só, não pode prever o risco de ninguém.

O que as pessoas que nascem com baixos níveis de LDL nos ensinam

Algumas pessoas herdam genes que lhes conferem baixos níveis de colesterol LDL desde o nascimento. Como esses genes são transmitidos aleatoriamente, eles funcionam como um experimento natural, e os resultados são impressionantes.

Em um estudo de longo prazo, os participantes negros que herdaram um variante genética que reduziram seu colesterol LDL em cerca de 28% tiveram um 88%: risco menor de doenças cardíacas ao longo de 15 anos [5]. Essa estimativa foi obtida a partir de um grupo de pessoas com poucos eventos cardíacos, portanto, sua margem de incerteza é ampla. Considerando muitos desses genes, cada 38,7 mg/dL (1 mmol/L) a menos de LDL ao longo da vida foi associado a aproximadamente metade o risco de doença cardíaca, cerca de três vezes maior do que o benefício por unidade observado quando as pessoas começam a tomar estatinas mais tarde na vida; trata-se de uma comparação aproximada entre tipos de estudos muito diferentes, e não de uma prova de que os dois sejam equivalentes [6].

Figura 8. Como se apresenta um risco menor associado ao 88%. Esses pontos ilustram uma redução do 88% aplicada a um ponto de partida fácil de visualizar, de 10 em 100; eles não representam os números reais do estudo. Essa variante hereditária específica, em um grupo de pessoas, foi associada a um risco significativamente menor de doença cardíaca coronariana; as estimativas genéticas e as de ensaios clínicos não são diretamente comparáveis [5].

Esses estudos genéticos são observacionais, e não ensaios clínicos de tratamento; portanto, seus resultados não podem ser comparados diretamente com os efeitos de um medicamento iniciado na idade adulta. Há também limitações. Uma variante comum não reduziu a incidência de derrames causados por obstruções [15]. Em outro grande estudo, PCSK9 Essas variantes reduziram o número de mortes por doenças cardíacas e vasculares, mas não alteraram o número de mortes por todas as causas [16]. O colesterol LDL baixo é uma proteção poderosa contra doenças cardíacas, mas não protege contra tudo.

Até que nível o LDL deve baixar?

Colesterol LDL O que sabemos Quão certos estamos?
Abaixo de 70 mg/dL Os tratamentos que reduziram o LDL abaixo desse nível diminuíram a incidência de ataques cardíacos e derrames em ensaios clínicos randomizados Tenho plena certeza de que os tratamentos funcionam; os ensaios clínicos testaram medicamentos, não o resultado exato Metas de LDL
Abaixo de 55 mg/dL Medicamentos adicionais que reduziram o LDL abaixo desse nível proporcionaram benefícios adicionais em ensaios clínicos randomizados Tenho plena certeza de que os tratamentos funcionam; os ensaios clínicos testaram medicamentos, não metas exatas de LDL
Cerca de 30 a 40 mg/dL Os grupos de tratamento em grandes ensaios clínicos randomizados atingiram esse nível e apresentaram melhores resultados Tenho quase certeza
Abaixo de 20 mg/dL As pessoas que atingiram esse nível baixo tiveram, em média, melhores resultados; não foi observado nenhum sinal significativo de risco nos desfechos analisados Tenho quase certeza, mas essas pessoas não foram designadas para esse nível
Abaixo de 10 mg/dL É a mesma direção, mas poucas pessoas chegam lá Menos certo

Milhares de pessoas nos grandes estudos alcançaram níveis de colesterol LDL abaixo de 20 mg/dL, e quanto mais baixos eram esses níveis, menor era a taxa de eventos. Nenhum sinal significativo de risco surgiu nos resultados analisados ao longo de um período de até cerca de oito anos, embora os efeitos raros ou a longo prazo permaneçam incertos [17, 18]. No entanto, essas pessoas não foram alocadas aleatoriamente para atingir níveis tão baixos, e nenhum estudo comparou diretamente a meta de 20 com a meta de 40.

Em termos simples. Níveis mais baixos de LDL têm, em geral, estado associados a um menor número de eventos, mesmo em níveis muito baixos. Os estudos analisados não identificaram um limite inferior claro para o benefício, mas as evidências tornam-se escassas em níveis extremos, e as melhores evidências abrangem níveis que vão até cerca de 30 a 40 mg/dL. Nenhum estudo designou participantes para metas específicas muito baixas.

Por que o risco nunca chega a zero

Figura 9. Entre os participantes selecionados para a extensão do estudo FOURIER, originalmente designados para receber evolocumab (colesterol LDL mediano de cerca de 30 mg/dL), ocorreram mortes por causas cardíacas, infarto do miocárdio ou acidente vascular cerebral a uma taxa de 2,05 eventos por 100 pessoas-ano durante a extensão, representada por 2 pontos marcados entre 100 pessoas-ano de acompanhamento; trata-se de uma taxa de eventos, e não da probabilidade de que uma determinada pessoa tenha um evento em um determinado ano. Esse não é o risco ao longo da vida para esse nível de LDL, e os participantes da extensão eram sobreviventes que optaram por continuar, não uma amostra aleatória [14].

Mesmo com níveis muito baixos de colesterol LDL, ainda ocorrem alguns ataques cardíacos e derrames, porque:

  • A placa bacteriana já formada não desaparece. Décadas de acúmulo diminuem apenas ligeiramente.
  • Alguns anos não conseguem desfazer o que quarenta anos fizeram. Reduzir o LDL aos 60 anos não pode apagar os efeitos da exposição sofrida nas décadas anteriores.
  • Outros fatores prejudicam as artérias. Lipoproteína(a), triglicerídeos, inflamação, tabagismo, alto pressão arterial, e o diabetes continuam sendo fatores importantes [19, 20].
  • Nem todo ataque cardíaco é causado por uma ruptura da membrana. Algumas são causadas por lesões no revestimento das artérias ou por coágulos provenientes de outras partes do corpo.

Um nível muito baixo de LDL é seguro?

O corpo produz seu próprio colesterol para o cérebro e os hormônios, e as evidências até o momento são tranquilizadoras. Em estudos com duração de até cerca de oito anos, níveis muito baixos de colesterol LDL não foram associados a um aumento claro de problemas de memória, derrames hemorrágicos, câncer ou outros efeitos colaterais graves nos desfechos analisados [21, 17, 18]. Os efeitos colaterais variam de acordo com o medicamento. As estatinas aumentam modestamente o risco de desenvolver diabetes em pessoas que já estão propensas a isso e podem causar dores musculares, embora danos musculares reais sejam raros [22]. Os medicamentos injetáveis à base de PCSK9 não apresentaram um sinal claro de diabetes em ensaios clínicos randomizados, mas podem causar reações leves no local da injeção [2]. Essas descobertas se aplicam apenas aos desfechos medidos, em voluntários selecionados, ao longo dos anos em que foram acompanhados; efeitos muito raros ou de longo prazo não podem ser descartados, e a segurança ao longo da vida com níveis extremamente baixos de LDL é desconhecida.

O que isso significa para você

Se você já teve um ataque cardíaco… Por que
Iniciar ou continuar o tratamento com uma estatina potente, geralmente antes da alta hospitalar É a base do tratamento
Saiba qual é o seu nível de colesterol LDL e qual é a sua meta Para pessoas com doenças cardíacas ou arteriais, as diretrizes dos EUA recomendam um nível inferior a 55 mg/dL caso atendam aos critérios de “risco muito alto” e inferior a 70 mg/dL nos demais casos, sendo que um nível inferior a 55 mg/dL é considerado razoável para algumas pessoas que não fazem parte do grupo de risco muito alto; um infarto recente, por si só, não coloca automaticamente a pessoa no grupo de risco muito elevado [23]
Se você ainda não atingiu sua meta, pergunte se é possível adicionar ezetimiba ou um inibidor da PCSK9 Esses medicamentos complementares reduzem ainda mais o LDL e diminuem a incidência de eventos
Peça para fazer um exame único de Lp(a) e pergunte se o exame de ApoB seria indicado no seu caso Esses fatores podem revelar riscos que os níveis de LDL não indicam
Não interprete uma tendência de alta escore de cálcio como um fracasso por si só Os níveis de cálcio podem aumentar à medida que a placa se torna mais estável, mas converse com seu médico sobre qualquer novo resultado; a repetição das exames de cálcio não é uma forma comprovada de avaliar o tratamento
Continue com o tratamento O benefício vai aumentando ao longo dos anos e vai diminuindo se você parar
Analisar o quadro como um todo Proibido fumar, pressão arterial e glicemia controle, reabilitação cardíaca e seus outros medicamentos para o coração

Perguntas a fazer ao seu cardiologista. Qual é o meu nível atual de colesterol LDL e qual deve ser minha meta? Estou no grupo de “risco muito alto”? Tomar outro medicamento me ajudaria a atingir minha meta? Devo fazer exames para verificar meus níveis de Lp(a) ou ApoB? Como vamos acompanhar se meu tratamento está funcionando?

O que ainda não sabemos

  • Se iniciar o uso de um segundo medicamento para o colesterol no hospital previne mais ataques cardíacos do que iniciá-lo algumas semanas depois. Um estudo recente, o AMUNDSEN, avaliou dois aspectos: quantas pessoas atingiram a meta de LDL (82% com a injeção precoce contra 40% com o tratamento padrão) e, como seu principal desfecho clínico, se o tratamento precoce reduziu as mortes ou as internações hospitalares não planejadas relacionadas a problemas cardíacos ao longo de um ano. Esse desfecho clínico não mostrou diferença significativa (razão de chances ajustada 0,94; 95% intervalo de confiança (0,73 a 1,19). O estudo foi grande o suficiente para detectar uma redução de aproximadamente um terço nesses eventos e não constatou tal redução, o que não sugere um benefício significativo no início; um benefício menor, ou que só se manifeste após mais de um ano, não foi descartado. Apenas cerca de 4% do grupo de cuidados habituais receberam esse tipo de medicamento durante o ano [24].
  • Se ter como meta 20 mg/dL é realmente melhor do que ter como meta 40 mg/dL.
  • É exatamente a extensão dessas alterações na placa que explica a redução no número de ataques cardíacos.
  • Quão seguro é manter níveis extremamente baixos de LDL ao longo de muitas décadas.

Palavras para aprender

Palavra O que isso significa
Colesterol LDL (LDL-C) O exame de sangue do “colesterol ruim”: a quantidade de colesterol transportada pelas partículas de LDL
ApoB Um exame de sangue que serve como um indicador útil da concentração de partículas transportadoras de colesterol, já que cada uma delas normalmente transporta uma molécula de ApoB
Placa Um acúmulo de colesterol, células e tecido cicatricial dentro da parede da artéria
Capa fibrosa A camada protetora que reveste o núcleo macio e gorduroso de uma placa
Estatina O medicamento de primeira escolha para reduzir o colesterol LDL
Inibidor da PCSK9 Um medicamento injetável (como o evolocumab ou o alirocumab) que reduz ainda mais o colesterol LDL
Ezetimiba Um comprimido que reduz o colesterol LDL ao bloquear a absorção do colesterol
Lp(a) Um tipo hereditário de partícula contendo ApoB que aumenta o risco cardíaco; geralmente é testado uma vez
OUT Uma minúscula câmera que utiliza luz e é capaz de capturar imagens do interior de uma artéria com grande detalhe
Placebo Um tratamento simulado utilizado para fins de comparação em estudos

Mergulho profundo

A placa que ninguém tratou

Imagine um paciente alguns dias após uma ataque cardíaco. O bloqueado artéria foi aberto, um stent mantém-no no lugar, e a dor no peito desapareceu. É natural pensar que o problema foi resolvido. Mas não foi. O stent tratou apenas um ponto em uma artéria. Espalhados pelo restante da árvore coronária, há outros placas, a maioria delas pequenas demais para parecerem preocupantes em um angiografia, e é daí que virão muitos dos próximos ataques cardíacos.

Isso não é especulação. O Estudo PROSPECT acompanhou 697 pacientes por três anos após um síndrome coronariana aguda. Ao longo de três anos, a taxa cumulativa do indicador composto do estudo de eventos cardiovasculares adversos maiores foi de 20,41 TP9T, cerca de um em cada cinco; esse valor representava uma combinação de morte cardíaca, parada cardíaca, ataque cardíaco ou reinternação por condição instável ou progressiva angina, e não apenas ataques cardíacos. Os eventos atribuídos aos locais de origem da lesão ocorreram em 12,9% dos pacientes, e os eventos atribuídos a placas não tratadas anteriormente, em 11,6%; alguns pacientes apresentaram ambos os casos, por isso a soma dos dois valores não corresponde ao total, e nem todo evento teve origem em uma placa não tratada anteriormente. A maioria das placas não tratadas que posteriormente causaram problemas apresentava apenas um estreitamento leve no angiograma original [8].

Portanto, a verdadeira questão após um ataque cardíaco não é apenas “O stent está funcionando?”. É “Será que podemos alterar o restante da doença antes que ela provoque o próximo evento?”. Este artigo analisa essa questão com base nas evidências: o que acontece dentro da placa quando Colesterol LDL é reduzido a níveis muito baixos; se isso se traduz em menos ataques cardíacos; qual é o nível baixo o suficiente; e por que o risco nunca chega a zero.

A resposta curta. Em estudos de imagem randomizados realizados após eventos coronarianos agudos, a redução intensiva do LDL-C produziu melhorias substanciais em marcadores selecionados de vulnerabilidade da placa, incluindo espessura da capa e teor lipídico, com reduções médias comparativamente modestas em volume da placa. Separate randomized outcome trials demonstrate fewer cardiovascular events with LDL-C lowering, but do not establish that the observed plaque-imaging changes mediate that benefit. Coronary disease does not disappear.

See Figure 1 in Part 1.

The Evidence at a Glance

Pergunta O que a evidência mostra Quão certos estamos?
Does very low LDL-C change plaque? Yes. Caps get thicker, lipid signals shrink, and plaque volume falls slightly. Shown in randomized imaging trials for specific imaging measures; not a validated substitute for events
Does lowering LDL-C prevent heart attacks and derrames? Yes. Large trials show fewer heart attacks, acidentes vasculares cerebrais isquêmicos, and procedures. Proven in large randomized trials
Does it reduce deaths? Yes for estatinas in pooled trials; for add-on drugs, only in nominal or open-label analyses. Proven for statins; suggestive for add-ons
Is lower still better below 20 or even 10 mg/dL? Lower achieved levels were associated with lower risk, compatible with benefit but subject to confundível and imprecision; no consistent major safety signal was detected in the populations and follow-up studied. Suggestive (not randomized to those levels)
Does time matter? Yes. Benefit grows over the years, and people with lifelong low LDL-C have far less coronary disease. Strongly supported
Can risk reach zero? No. Events still occur even at extremely low LDL-C. Consistent across all data
Do the plaque changes cause the fall in events? Plausible, but not proven. Inference

Inside a Heart Attack

To understand what Huygens measured, it helps to know what a dangerous plaque looks like.

See Figure 2 in Part 1.

A plaque is a buildup inside the artery wall, not a deposit stuck on the inside of a pipe. It has several parts:

  • Lipid-rich or núcleo necrótico: a pool of colesterol, cristais de colesterol, and debris from dead cells. It is soft, mechanically weak, and strongly clot-promoting if blood reaches it.
  • Capa fibrosa: a collagen layer, built by células musculares lisas, that walls the core off from the bloodstream. In autopsy studies of sudden coronary death, ruptured caps were typically thinner than about 65 micrometers (μm), roughly the width of a fine human hair [25].
  • Macrófagos: immune cells that swallow cholesterol and become “células espumosas.” They release enzymes that can digest the collagen in the cap.
  • Calcium: mineral deposits. Small, spotty calcium in an active plaque may concentrate stress, while large, dense sheets often mark older, more fibrous disease. Extensive calcium remains a marker of carga de placa and risk.

Most heart attacks begin when a thin cap tears (rupture) and blood meets the clot-promoting core. A smaller share begin with erosion, in which the artery’s inner lining wears away over a firmer, less fatty plaque [26]. That difference will matter later, because thickening a cap mainly protects against rupture.

How Cholesterol Gets Into the Wall

LDL cholesterol does not float into the artery wall as loose fat. It travels inside particles, and it is the particles that cross the artery lining, get trapped, and are swallowed by macrophages. Each of these particles, whether LDL, a triglyceride-rich remnant, or Lp(a), carries one molecule of a proteína chamado apolipoproteína B (ApoB): ApoB-100 on particles made by the liver, and the shorter ApoB-48 ativado quilomícro remnants from the intestine.

See Figure 3 in Part 1.

In plain terms: ApoB is the traffic count; LDL-C is the cholesterol cargo. The standard lab value, LDL-C, measures how much cholesterol the LDL particles carry. The ApoB test measures ApoB mass concentration, which serves as a proxy for particle number because each major partícula aterogênica carries one ApoB-100 molecule; it does not literally count particles. Usually the two move together. When they disagree, as can happen with high triglicerídeos, diabetes, obesidade, or small LDL particles, ApoB may better reflect how many particles can enter the artery wall.

For readers who use international units, these are the approximate conversions at the LDL-C levels discussed in this article (rounded; for example, 40 mg/dL is about 1.03 mmol/L, so the rounded values are not exactly equivalent thresholds):

LDL-C (mg/dL) 70 55 40 30 20 10
LDL-C (mmol/L) 1.8 1.4 1.0 0.78 0.52 0.26

Looking Inside a Living Artery

For most of the history of cardiology, nobody could see a fibrous cap in a living person. Angiograms show only the silhouette of the open channel. That changed with catheters that image the artery from the inside.

Figura 10. Approximate resolution of imagem coronariana methods (typical ranges; vary by system). Only OCT resolves detail finer than a vulnerable fibrous cap, so cap-thickness results come from OCT, while plaque volume comes from IVUS, which sees through the full wall. Near-infrared spectroscopy (NIRS, not shown) detects the chemical signature of lipid rather than structure. None of these is a microscope: tissue labels are inferences.

Imaging tool What it is good at What it cannot do well
OCT (light) Measures cap thickness, arco lipídico, macrophage-like signals, calcium, clot Cannot see total plaque volume behind lipid
IVUS (ultrasound) Measures plaque volume and how the artery has remodeled Too coarse to measure a cap
NIRS (spectroscopy) Detects the chemical signature of lipid Cannot measure caps or volume on its own
Coronary CT Shows plaque across the whole heart without a catheter Cannot see caps or fine detail

None of these is a microscope. The tissue labels they produce are inferences from how light or sound behaves. An OCT increase in cap thickness, a NIRS decrease in lipid, and an IVUS decrease in plaque volume are complementary findings, not interchangeable ones.

The HUYGENS Experiment

HUYGENS (High-Resolution Assessment of Coronary Plaques in a Global Evolocumabe Randomized Study) was built to answer one question: if LDL cholesterol is pushed very low right after a heart attack, do the dangerous-looking plaques elsewhere in the heart change? It was a phase 3, multicenter, randomized, double-blind, placebo-controlled imaging trial [9, 1]. Amgen, which makes evolocumab, funded it, and several investigators reported financial ties to the company [9].

Who Took Part

The investigators deliberately chose people whose remaining plaques already looked vulnerable. Patients had a non-ST-elevation heart attack (NSTEMI) treated with angiography and a procedure on the culprit artery. They needed LDL-C above a threshold that depended on their statin use (at least 130 mg/dL on no statin, 80 mg/dL on a low- or moderate-intensity statin, or 60 mg/dL on a estatina de alta intensidade), and a separate, untreated artery segment at least 40 mm long showing placa rica em lipídios on OCT: a cap no thicker than 120 μm and a lipid arc greater than 90 degrees [9].

Everyone took a maximally tolerated statin. Half were also randomized to evolocumab 420 mg, an injected Inibidor da PCSK9, and half to a placebo injection, monthly through week 48, with repeat OCT and IVUS at about week 50 to 52 [9]. HUYGENS included 161 randomized and treated patients (80 evolocumab, 81 placebo). Of the treated patients, 135 had evaluable imaging at follow-up, and a smaller subset had paired IVUS, The registry results report the OCT endpoints for the full analysis set of all 161 treated patients, of whom 119 had paired OCT measurements of the primary endpoint, so the analysis did not directly reimage all 161; the IVUS results come from a smaller subset [1]. Participants averaged 60.5 years of age, and 28.6% were women.

How Low LDL Went

Mean LDL-C at enrollment was 141.3 mg/dL. At follow-up it was 28.1 mg/dL with evolocumab versus 87.2 mg/dL with placebo [1]. The placebo group was not untreated: many patients entered on no statin or a low dose, so their fall from about 141 to 87 mg/dL largely reflects starting or strengthening a statin. Every HUYGENS comparison is statin versus statin plus evolocumab.

What Happened to the Plaque

See Figure 4 in Part 1.

The protective cap thickened by an average of +42.7 μm with evolocumab versus +21.5 μm with placebo, least-squares means from the trial’s analysis of covariance in all 161 treated patients (the full analysis set, per the trial’s registry results); a difference of 21.2 μm (95% CI 4.7–37.7; P=0.015) [1]. The lipid arc shrank more (−57.5 versus −31.4 degrees), and the macrophage signal fell more. Plaque volume, measured by IVUS in an exploratory subset, changed only modestly: volume percentual de ateroma change −2.29 versus −0.61 percentage points, an arithmetic difference of −1.68 points (not an adjusted contrast, and not directly comparable with PACMAN-AMI’s model-based estimate).

Em termos simples. The average increase in cap thickness was about twice as large with evolocumab. That compares the size of the increases, not the caps themselves, and it does not mean heart-attack risk was halved. The big change was in what the plaque is made of, not in how large it is. These results describe the selected nonculprit segments that were imaged, not every plaque in the coronary tree.

A secondary review by trial investigators also reported fewer evolocumab-treated patients with very thin caps (below 65 μm) after treatment [27]. The full HUYGENS results table is in the Technical Appendix.

Two later HUYGENS analyses looked for patients who responded differently. Patients with high Lp(a) showed a larger difference in cap thickening between evolocumab and placebo [28], and patients who reached lower ApoB levels had more favorable plaque findings than those who did not [29]. Both are small, post hoc subgroup analyses: they were not randomized to those levels, they need replication, and they do not establish an independent treatment target or mechanism. Details are in the Technical Appendix.

What HUYGENS Cannot Tell Us

HUYGENS provides randomized evidence that adding evolocumab to statin therapy after NSTEMI improves several OCT-derived features associated with plaque vulnerability in selected nonculprit coronary lesões. It does not establish that these imaging changes directly prevented later cardiovascular events.

Huygens was not designed to show fewer heart attacks, strokes, or deaths. That would take tens of thousands of patients, not 161. It imaged only at the start and at one year, so it cannot say how quickly caps change. It studied people chosen because their plaques already looked vulnerable. And it cannot show that thicker caps caused any later drop in events. For that, we need other kinds of trials.

Not a One-Off: Other Trials Saw the Same Thing

A single 161-patient trial would be easy to dismiss. HUYGENS is persuasive because other trials, using different drugs and different imaging tools, saw the same pattern.

PACMAN-AMI randomized 300 heart attack patients para alirocumabe, another PCSK9 antibody, or placebo, both on top of rossuvastatina, starting within 24 hours after urgent PCI for the heart attack, and assessed nonculprit plaques with complementary imaging methods. Among the 300 randomized participants, paired IVUS was available in 265; the NIRS lipid analysis included 263 patients, and the OCT cap-thickness analysis 221 patients (105 alirocumab, 116 placebo) who had a fibroateroma at both time points. All three measurements came from the same randomized trial. LDL-C fell to 23.6 mg/dL versus 74.4 mg/dL. Three complementary imaging modalities, measured in overlapping patients within the same trial, showed concordant favorable changes: percent ateroma volume fell more (difference −1.21 percentage points), the NIRS lipid signal fell more (difference −41.24), and cap thickness rose more (+62.67 versus +33.19 μm; difference +29.65 μm) [7]. These differences are the trial’s model-based estimates. When light, sound, and chemistry agree within one trial, the finding is more convincing than any single measure, though it is still one trial.

Figure 11. HUYGENS and PACMAN-AMI: change over about one year in each treatment arm. Both trials added a PCSK9 antibody (evolocumab in HUYGENS, alirocumab in PACMAN-AMI) to statin therapy after infarto do miocárdio. Bars are within-arm mean changes as reported; the between-group differences were +21.2 μm (P=0.015) and +29.65 μm (11.75–47.55) for cap thickness, and −1.68 (arithmetic) and −1.21 (−1.78 to −0.65) percentage points for percent atheroma volume. For PACMAN-AMI, simple subtraction of the arm means gives 29.48 μm, slightly different from the trial’s model-adjusted 29.65 μm because the trial’s mixed-effects model accounts for repeated measurements and for the multiple arteries imaged in each patient; the text uses the adjusted figure. The two panels use different units and should not be compared with each other. HUYGENS percent atheroma volume was an exploratory endpoint in an IVUS subset. Analysis populations differ by measure: HUYGENS cap results are model estimates in the full analysis set of 161 treated patients (119 with paired OCT; 135 with any evaluable follow-up imaging) and its PAV comes from a smaller IVUS subset; PACMAN-AMI’s PAV comes from 265 patients with paired IVUS and its cap thickness from 221 patients with a fibroatheroma at both time points. Sources: [1, 7].

GLAGOV randomized 968 patients (846 with evaluable follow-up IVUS) with stable coronary disease to evolocumab or placebo for 76 weeks, with the main IVUS scan at week 78. LDL-C averaged 36.6 versus 93.0 mg/dL. Percent atheroma volume changed by −0.95 percentage points with evolocumab versus +0.05 with placebo (between-group difference −1.0 percentage point; 95% CI −1.8 to −0.64, reproduced verbatim from the published trial), and 64% versus 47% of patients had measurable regression [30]. These are within-arm changes plus the trial’s reported between-group contrast, not percent reductions in plaque mass. In an exploratory subgroup that reached about 24 mg/dL, 81% regressed. GLAGOV also shows the limits: about a third of treated patients did not regress, and a tissue-analysis substudy found no significant differences in plaque components [31].

Earlier statin and ezetimiba trials told the same story at higher LDL-C levels: lower LDL-C meant less plaque growth or modest regression [32, 33, 34, 35], and thicker caps on OCT [36]. YELLOW III documented favorable within-person changes in plaque-imaging measurements over 26 weeks; because it was uncontrolled, it cannot establish how much of the change was due to evolocumab [37]. A 2025 single-arm evolocumab CT/PET study reported less placa não calcificada and lower microcalcificação activity, while placa calcificada volume rose; its imaging endpoints measure different things and should be read individually [38]. Not every trial was positive: ODISSEIA J-IVUS found no significant difference in its plaque endpoint over 36 weeks [39].

Figure 12. Change in IVUS percent atheroma volume in each arm of five randomized imaging trials, one panel per trial, with each arm’s achieved LDL-C. Compare arms only within a panel: populations, durations (9 to 24 months), and LDL-C measures (GLAGOV is time-weighted) differ, so the panels are not evidence of a common dose–response relationship. HUYGENS values come from an exploratory IVUS subset. Saturno reported median changes and time-weighted LDL-C, whereas the other trials report means. ASTEROIDE is omitted because it had no comparator arm, and ODYSSEY J-IVUS because absolute achieved LDL-C was not available in the sources reviewed. Sources: [34, 35, 30, 1, 7].

What does a one-point drop in plaque volume mean? Percent atheroma volume (PAV) is the share of the vessel’s area taken up by plaque. A change from 40% to 39% is a one-percentage-point drop. It does not mean 1% of all plaque disappeared, and it does not mean a narrowing opened by the same amount.

Figure 13. Conceptual illustration of the scale of a one-percentage-point change in percent atheroma volume (PAV); the open channel (lúmen) is drawn the same size in both panels, and the outer vessel boundary shrinks slightly. PAV is the share of the vessel’s area occupied by plaque, averaged along a segment. A fall from 40% to 39% is the scale of change in the IVUS trials. It is not 1% of all plaque disappearing, and it does not mean the open channel widened by a matching amount, because arteries also remodel.

A side-by-side table of all the imaging trials is in the Technical Appendix.

Different, Not Much Smaller

If plaque volume barely changes, how could a plaque become less likely to rupture? Mechanics offers a plausible answer. Rupture happens when stress concentrates in a thin cap stretched over a soft core. Less lipid and a thicker cap should lower that stress even if the plaque is almost the same size. That offers a plausible explanation for how outcome trials can show meaningful reductions in events while imaging trials show only small changes in volume, though it remains an interpretation, not a demonstrated cause.

Figure 14. Illustrative schematic—not an observed patient or a guaranteed treatment response. Conceptual diagram of estabilização da placa: not drawn to scale and not derived from patient images. Randomized imaging trials show cap thickening, less lipid, fewer macrophage-like signals, and a small decrease in plaque volume. Calcium changes and lesion anatomy are illustrative, not measured transitions in a single plaque. Randomized trials do not show plaque elimination, calcium removal, or routine lumen enlargement.

The chain of reasoning from lower LDL-C to fewer heart attacks has several links. Some are measured directly; others are inferred.

Figure 15. How lower LDL-C relates to plaque imaging and to clinical events. Fewer ApoB particles and fewer events are both established, the second in large outcome trials. Lipid, macrophage-like, and cap findings are parallel imaging surrogates measured together, not a proven sequence. Whether these imaging changes mediate the reduction in events has not been established.

Observational imaging supports the idea that these features matter. In the CLIMA study, untreated plaques that combined four high-risk OCT features carried a several-fold higher one-year risk of events [40]. Linking a feature to risk, however, is not the same as proving that changing the feature lowers risk.

Three cautions keep this in proportion:

  • A thicker cap is not a guarantee. The 65 μm cutoff comes from autopsy studies [25]. Thicker caps can still rupture, OCT measurement of such thin structures varies, and cap thickness varies along its length.
  • Erosion is different. Heart attacks from erosion are driven more by injury to the artery lining and inflamação than by cap thinning [26]. Cap thickening mostly addresses rupture, which is one reason events still occur at very low LDL-C.
  • Calcium may go up, not down. High-intensity statins increased IVUS calcium measures while reducing plaque volume [41], and statin users in the PARADIGM CT cohort had slower growth of noncalcified plaque but faster growth of calcified plaque [42]. A rising escore de cálcio on treatment does not, by itself, mean treatment has failed, and serial calcium scores are not a validated way to judge treatment. Claims that LDL lowering “dissolves calcium” are not supported.

Nor does regression necessarily reopen the artery. A reduction in percent atheroma volume does not necessarily translate into a comparable increase in lumen diameter. Coronary arteries can remodel outward or inward, and regressão de placa may occur without a clinically meaningful change in the narrowing seen on an angiogram. The imaging trials discussed here do not establish routine reversal of fixed coronary narrowing.

From Better-Looking Plaque to Fewer Heart Attacks

Imaging trials show what happens to plaque. Outcome trials, which enroll thousands of patients and count actual heart attacks, strokes, and deaths, show whether it matters. This is the strongest evidence in the story.

Figure 16. How the evidence in this article is weighted. Randomized outcome trials establish that lowering LDL-C prevents the events they tested; randomized imaging trials show that it changes imaging measures of plaque; the remaining tiers support, but cannot by themselves prove, claims about very low targets, long-term legacy, and lifelong benefit. Each claim in the text is labeled by the kind of evidence behind it.

The Numbers That Matter to Patients

Relative reductions sound large; absolute reductions show what a person gains. In Fourier, the primary composite (cardiovascular death, heart attack, stroke, hospitalization for angina instável, ou coronariana revascularização) occurred in 9.8% with evolocumab versus 11.3% with placebo over a median 2.2 years: a 15% relative hazard reduction and an absolute difference of about 1.5 percentage points, or about 15 fewer people per 1,000 [2]. That composite is not the chance of a heart attack alone, and the original Estudo FOURIER did not establish a reduction in death.

See Figure 5 in Part 1.

Avaliação What was tested Acompanhamento Event rate, treatment vs control Difference per 1,000 (people; FOURIER-OLE: events per 1,000 person-years)
MIRACL [43] High-dose statin vs placebo, started in hospital 16 weeks 14.8% vs 17.4% About 26
PROVE IT–TIMI 22 [10] Intensive vs moderate statin 2 anos 22.4% vs 26.3% About 39
IMPROVE-IT [4] Adding ezetimibe to a statin 7 years 32.7% vs 34.7% About 20
RESULTADOS DO PROJETO ODYSSEY [3] Adding alirocumab after ACS Median 2.8 years 9.5% vs 11.1% About 16
FOURIER [2] Adding evolocumab, stable disease Median 2.2 years 9.8% vs 11.3% About 15
FOURIER-OLE [14] (open-label extension; not a randomized trial endpoint) Earlier vs later evolocumab (open label) Median 5 more years CV death, MI, or stroke 2.05 vs 2.58 per 100 person-years About 5.3 fewer events per 1,000 person-years (rate difference, not people)

Each trial counted its own combination of events in its own population over its own follow-up, so the rows are not a ranking. FOURIER-OLE compares original randomized assignment in selected survivors, all on open-label evolocumab. A detailed version of this table, with relative effects, LDL-C levels, and mortality, is in the Technical Appendix.

Figure 17. Absolute benefit in the major outcome trials, shown as small multiples: each panel gives one trial’s control and treated primary-endpoint event rates on its own y-axis scale, with the difference expressed per 1,000 patients treated. Each trial used a different endpoint composto, population, comparator, and follow-up period, so the panels cannot be compared with one another or read as a ranking; they show the scale of benefit within each trial. *FOURIER-OLE shows cardiovascular death, MI, or stroke during the open-label extension, comparing patients originally assigned evolocumab with those originally assigned placebo (2.58 vs 2.05 events per 100 person-years); because this is a rate, not a percentage of patients, its panel has its own y-axis label; it is an exploratory comparison in selected survivors, not a new randomized trial. Sources: [43, 10, 4, 3, 2, 14].

Figure 18. Selected outcome estimates from the trials discussed: primary endpoints for the randomized trials, the open-label extension comparison for FOURIER-OLE, and the main clinical end point for AMUNDSEN. Each trial used a different composite endpoint, population, and follow-up, and reported a different effect measure (risk ratio, razão de riscos, or adjusted odds ratio), so each effect measure is shown in its own panel with its own axis, for orientation, not pooled or ranked. Absolute differences are crude differences in each trial’s reported event rates over its own follow-up (for FOURIER-OLE, per 100 person-years). FOURIER-OLE is not a newly randomized outcome comparison: it compares selected surviving participants by original assignment during an open-label extension in which all received evolocumab. AMUNDSEN (gray) is shown for its main clinical end point, which was tested second in the trial’s prespecified hierarchy, after the LDL-C target endpoint; the trial was powered for it. PROVE IT–TIMI 22’s interval is derived from its reported 16% (5%–26%) relative reduction. MIRACL’s risco relativo is shown as the trial reported it, estimated from a Cox proportional hazards model. Sources: [43, 10, 4, 3, 2, 14, 24].

Fewer Heart Attacks and Strokes; Death Is Harder to Move

The benefit is concentrated in nonfatal events. In FOURIER, heart attacks fell from 4.6% to 3.4%, strokes from 1.9% to 1.5%, and coronary procedures from 7.0% to 5.5% [2]. ODYSSEY OUTCOMES and IMPROVE-IT showed similar reductions in heart attack and ischemic stroke [3, 4]. These are secondary analyses that support the main findings.

Among the add-on trials (IMPROVE-IT, ODYSSEY OUTCOMES, and FOURIER), none showed a reduction in death that was statistically significant under its prespecified rules. ODYSSEY OUTCOMES’ lower all-cause death rate was nominal only. This does not prove that there is no mortality benefit; it means one should not be claimed as proven for these drugs individually.

Counting Every Event

Trials usually count only each patient’s first event. But a patient who has one heart attack often has another, or a stroke, or a stent. When FOURIER counted every event, the estimated number of events prevented more than doubled, although the relative risk reduction did not: about 22 first events but 52 total events prevented per 1,000 patients treated for three years, counting first and repeat events rather than additional people helped (total events: rate ratio 0.82, 95% CI 0.75–0.90; first events: hazard ratio 0.85) [11].

See Figure 6 in Part 1.

The Big Picture

The Cholesterol Treatment Trialists pooled individual data from 26 statin trials and about 170,000 people. Each 38.7 mg/dL (1 mmol/L) reduction in LDL-C lowered major vascular events by about 22%, and all-cause death fell by about 10% per mmol/L, with no increase in cancer or other non-cardiovascular deaths [12]. A meta-regression of randomized trials found broadly similar proportional risk reductions per unit of LDL-C lowering across statins, ezetimibe, and PCSK9 inhibitors, which act through LDL-receptor pathways [13]. That supports a common LDL-mediated mechanism, though it does not mean every drug has identical clinical effects or safety profiles.

Em termos simples. The absolute LDL-C reduction and how long it lasts are major determinants of benefit, but therapies differ in evidence, timing, off-target effects, and tolerability.

Do the plaque changes explain this benefit? Plausibly, in part. The same drugs at similar LDL-C levels improve plaque in imaging trials and reduce events in outcome trials. But the imaging and outcome trials enrolled different people, and no trial has shown that the imaging changes account for the event reduction. The plaque findings make the benefit biologically coherent; the outcome trials establish the benefit for the endpoints they tested.

Time Is the Hidden Ingredient

Perhaps the most important lesson in the newer data is that benefit builds over time.

The Lag Effect

In FOURIER, the relative reduction in cardiovascular death, heart attack, or stroke was about 16% in the first year and about 25% after the first year [2]. Earlier statin trials showed the same pattern: benefit grows the longer treatment continues. That is consistent with, though it does not prove, plaque gradually becoming more stable.

The Legacy Effect

FOURIER did not demonstrate a significant cardiovascular mortality benefit during its median 2.2-year randomized phase. Afterward, 6,635 surviving participants who chose to continue entered an open-label extension, FOURIER-OLE, in which everyone received evolocumab; median extension follow-up was 5.0 years, and maximum evolocumab exposure across the parent trial and extension reached about 8.4 years; median LDL-C during the extension was about 30 mg/dL [14].

Even though both groups were now on the same drug at similar LDL-C, those originally assigned evolocumab, about two years earlier, had fewer subsequent events. Cardiovascular death, heart attack, or stroke occurred at 2.05 versus 2.58 events per 100 person-years (HR 0.80; 95% CI 0.68–0.93), and cardiovascular death at 0.68 versus 0.90 per 100 person-years (HR 0.77; 95% CI 0.60–0.99), as reported in the results table of the primary FOURIER-OLE publication, where events were counted during extension follow-up by original randomized assignment [14]. This is an exploratory comparison among selected survivors in open-label follow-up, not a new blinded randomized trial, so it cannot establish a mortality benefit by itself. It is compatible with a legacy effect from earlier, longer LDL lowering, but selection into the extension and open-label treatment mean it cannot show that early treatment caused the difference, or what carried it forward.

Figure 19. FOURIER-OLE: event rates per 100 person-years during the open-label extension, when all 6,635 participants received evolocumab and median LDL-C was about 30 mg/dL. Patients first randomized to evolocumab had 2.2 more years of low LDL-C exposure. Even in that group, cardiovascular death, MI, or stroke occurred at about 2 per 100 person-years. Extension participants were selected survivors and treatment was open label. Source: [14]. These are event rates in a selected-survivor, open-label extension; they cannot prove a randomized mortality benefit.

How Fast Things Change

  • LDL-C falls within days with a PCSK9 antibody and within two to four weeks with a statin. In AMUNDSEN, median LDL-C was 16 mg/dL six weeks after evolocumab was started before stenting, versus 56 mg/dL with standard care [24].
  • Placa changes in the randomized imaging trials were measured after roughly 9 to 24 months. YELLOW III documented within-person changes at 26 weeks, but it was uncontrolled, so it cannot establish the size of the drug’s effect or how early it began [37]. A trial that imaged only at the start and at one year cannot show that caps began thickening within days.
  • Clinical events: MIRACL showed fewer recurrent ischemic events within 16 weeks [43]; FOURIER’s curves separated within about six months [2]; FOURIER-OLE’s exploratory cardiovascular-death difference emerged only during the open-label extension [14].

Figure 20. Timeline separating measured LDL-C changes, measured plaque changes, and observed clinical benefit. Each cell shows when a study made a measurement, not when a biological effect began; the figure cannot show when stabilization started, and no unmeasured time points are extrapolated. The time of a study measurement is not necessarily the time a biological benefit began; clinical benefit can begin before imaging is repeated, and no fixed biological lag is implied. A blank cell means not measured, not no effect.

Exposure Over a Lifetime

Why should time matter so much? Because aterosclerose reflects the total, accumulated exposure of the artery wall to ApoB particles over a lifetime. Genetic studies indicate that exposição cumulativa drives risk [44]. A person treated after a heart attack lowers their future exposure but carries decades of past exposure and the plaque it built.

See Figure 7 in Part 1.

How much a patient gains depends on three things together: baseline risk, how much LDL-C falls, and how long it stays down. The same LDL reduction prevents far more events in a high-risk patient, and larger sustained reductions prevent more.

Figure 21. Evidence summary, not a patient-specific prediction. Lines apply the Cholesterol Treatment Trialists’ estimate of a 22% lower risk of major vascular events per 38.7 mg/dL (1 mmol/L) of LDL-C lowering over about five years [12] to three illustrative baseline five-year risks. The same LDL-C reduction prevents more events in higher-risk patients, and larger sustained reductions prevent more. Longer duration adds further benefit beyond what a five-year estimate shows (see the lifetime-exposure figure). Reductions above about 80 mg/dL extend beyond much of the trial data. Assumptions: the CTT rate ratio (a relative risk from a metanálise, not a trial hazard ratio) is applied uniformly at every baseline risk and scales log-linearly with LDL-C reduction. This is not a patient calculadora de risco.

Até que nível o LDL deve baixar?

Patients often ask whether 40 is good enough, or whether 20 or 10 is better. The honest answer depends on what kind of evidence you accept, because the lower one goes, the more the evidence shifts from randomized comparisons to observational ones.

LDL-C level What the evidence looks like Resultado final
Abaixo de 70 mg/dL Randomized trials (PROVE IT, statin imaging trials) Established for drug regimens that reached these levels (not randomized to the threshold)
Abaixo de 55 mg/dL Randomized trials (IMPROVE-IT, ODYSSEY, FOURIER) Established for drug regimens that reached these levels (not randomized to the threshold)
Below 40 mg/dL Randomized trial arms reached it (FOURIER about 30; GLAGOV 36.6) Strongly supported
Below 30 mg/dL Imaging trials (HUYGENS 28, PACMAN-AMI 24); achieved-level analyses Supported for plaque; outcomes observational
Abaixo de 20 mg/dL Thousands of patients in FOURIER and FOURIER-OLE reached it, but were not randomized to it Lower risk, no clear safety signal; observational
Abaixo de 10 mg/dL Small subsets of FOURIER, FOURIER-OLE, and ODYSSEY Consistent but statistically fragile

No trial cited here randomized post-heart-attack patients between specific LDL-C targets below 55 mg/dL. People in the drug trials were randomized to drugs, not to “20 versus 40.” That is the most important caveat in this area.

Within those limits, the data point one way. In FOURIER, 2,669 participants reached LDL-C below 20 mg/dL (0.5 mmol/L) by week 4; lower achieved LDL-C was associated with steadily lower cardiovascular risk across the range studied, and serious adverse events were not related to achieved LDL-C over the randomized period [17]. In FOURIER-OLE, about 1,604 participants maintained LDL-C below 20 mg/dL; lower levels remained associated with lower risk and no detected increase in serious adverse events over the extension’s follow-up [18]. In ODYSSEY OUTCOMES, patients who transiently reached below 15 mg/dL had fewer subsequent events in an adjusted post hoc comparison (HR 0.72; 95% CI 0.51–0.997), which does not establish that aiming below 15 mg/dL is better [45].

Em termos simples. Lower achieved LDL-C has generally been linked to lower event rates across the ranges examined, including very low levels. The studies reviewed have not identified a clear lower threshold; evidence becomes sparse at extreme LDL-C, and achieved-level analyses cannot identify the best target. No randomized trial has shown that aiming for 10 or 20 mg/dL beats aiming for 30 or 40 mg/dL.

How Low Can Risk Go?

There is a different question hiding inside “how low should LDL go.” Suppose LDL-C is pushed nearly to zero. How low can the rate of heart attack, stroke, and cardiovascular death fall? The answer differs sharply between people who already have coronary disease and people who have had low LDL-C since birth.

In People Who Already Have Atherosclerosis

This is not a randomized comparison of LDL-C targets: patients sorted themselves into achieved-LDL groups, so selection and confounding can only partly be adjusted for, and the analysis does not prove there is no biological floor. Within that limit, the peer-reviewed FOURIER-OLE achieved-LDL analysis found risk falling steadily down to the lowest levels studied, below 20 mg/dL [18].

Two points follow. Risk was lowest at the lowest achieved levels studied, an observational association. And the floor is well above zero: among selected participants entering FOURIER-OLE, cardiovascular death, heart attack, or stroke occurred at 2.05 events per 100 person-years of follow-up in those originally assigned evolocumab, the group treated longest; this is a rate by original randomized assignment, not the risk at an LDL-C of 30 mg/dL [14].

These are observational comparisons within trials; patients who reach the lowest levels may differ in ways that statistical adjustment cannot fully remove.

Why the Floor Exists

  • Plaque already built. These patients carried decades of accumulated plaque, and IVUS shows plaque burden falling by only a few percentage points.
  • Short exposure. Two to eight years of very low LDL-C cannot erase forty or more years of higher exposure.
  • Other pathways. Lp(a), triglyceride-rich remnants, and residual inflammation persist. In CANTOS, COLCOT, and LoDoCo2, anti-inflammatory therapy reduced events in patients already on lipid-lowering drugs [19, 20, 46].
  • Other causes. Some strokes come from the heart or tiny vessels, and some heart attacks from erosion, artery tears, or clots carried from elsewhere. Fumo, pressão arterial, diabetes, and doença renal also continue to drive risk.

Nature’s Experiment: People Born With Low LDL

Some people inherit variantes genéticas that lower LDL-C from birth. Because those variants are assigned at conception, largely independent of lifestyle, they act like natural randomized experiments. Their results are dramatic.

See Figure 8 in Part 1.

  • PCSK9 nonsense variants. No ARIC study, Black participants carrying inactivating PCSK9 variants had about 28% lower LDL-C and an 88% lower risk of doença cardíaca coronariana over 15 years. White participants with a milder variant had about 15% lower LDL-C and 47% lower risk [5]. Few carriers had events, so the estimate is imprecise (hazard ratio 0.11; 95% CI 0.02–0.81).
  • APOB truncating variants. Carriers had 43 mg/dL lower LDL-C and 72% lower odds of early coronary disease [47].
  • PCSK9 R46L in large studies. This common variant lowers LDL-C only modestly, yet it was associated with less coronary or doença cardíaca isquêmica [48, 15] and lower cardiovascular mortality [16].
  • Across nine variants in six genes (312,321 people), each 38.7 mg/dL of lifelong lower LDL-C was associated with 5% lower coronary risk, about three times the effect per unit of statins started later in life; this is an illustrative comparison across different study designs, not causal equivalence [6].

The genetic data also mark limits. The same R46L variant that lowered coronary risk was not associated with lower ischemic stroke [15], and lifelong lower LDL-C from PCSK9 variants was associated with lower cardiovascular but not mortalidade por todas as causas [16]. Across these datasets, reductions in ischemic stroke or all-cause mortality were not consistently demonstrated; estimates differ by variant, population, endpoint, and statistical precision. These are observational genetic associations with population-specific uncertainty. Effect sizes differ across variants, populations, and endpoints, and because they reflect lifelong exposure, their scale cannot be equated with a drug treatment effect started in adulthood; quantitative comparisons with trials are illustrative.

People who inherit two inactivating PCSK9 variants are extremely rare. The best-documented case is a 32-year-old woman with no detectable PCSK9 and LDL-C of 14 mg/dL who was healthy, fertile, and working as an aerobics instructor [49]. She was described at a single point in time; nobody knows her long-term cardiovascular outcome.

Putting the Two Together

Figure 22. Illustrative model, not trial data or a patient risk calculator. Lines show two published log-linear associations with different endpoints, populations, and exposure durations: the Cholesterol Treatment Trialists’ rate ratio of 0.78 (95% CI 0.76–0.80) for major vascular events per 38.7 mg/dL over about five years of statin treatment [12], and the Randomização mendeliana estimate of 54.5% (95% CI 48.8%–59.5%) lower coronary heart disease risk per 38.7 mg/dL of lifelong exposure, from 312,321 participants and 9 variants in 6 genes [6]. Each curve is ratio^(LDL-C difference/38.7); shaded bands carry each published 95% intervalo de confiança through the same formula and are not observed trial confidence bands. Extrapolated segments are dashed: in panel B beyond about 40 mg/dL, past the range of most genetic variants, and in panel A beyond about 80 mg/dL, past most trial LDL-C reductions, and the model assumes the relação log-linear holds at extreme exposures, which has not been shown. The two estimates are shown in separate panels, without individual study or trial points, because their endpoints and populations differ; they must not be read as a head-to-head comparison of statin therapy with lifelong genetic LDL reduction or as a prediction of individual lifetime risk.

The figure compares two published estimates. Applied to a difference of about 75 mg/dL, the statin-trial estimate predicts roughly 38% fewer major vascular events over about five years, while the genetic estimate predicts roughly 78% fewer coronary events over a lifetime. Both are extrapolations, especially the genetic one. They illustrate why duration matters, not what any individual should expect.

The defensible conclusion. Early, sustained, very low exposure to ApoB particles probably drives atherosclerotic coronary events toward a low floor. But no human data show near-zero cardiovascular events, the genetic data suggest stroke and total mortality would remain above zero, and in people who already have coronary disease, events still occur even at extremely low LDL-C.

Um nível muito baixo de LDL é seguro?

A natural worry is that the body needs cholesterol. It does, but cells make their own, and the evidence so far is reassuring, with honest limits.

  • Memory and thinking. In EBBINGHAUS, 1,204 FOURIER patients underwent formal cognitive testing over a median 19 months, with no difference between evolocumab and placebo and no link to achieved LDL-C [21]. Longer follow-up found no excess of reported cognitive events [18], though that relies on adverse-event reports.
  • Bleeding strokes. Dose alta atorvastatina after stroke modestly increased derrame hemorrágico in SPARCL [50]. FOURIER, ODYSSEY OUTCOMES, and the very-low-LDL analyses showed no significant excess [2, 17, 18], though such strokes are uncommon.
  • Statins modestly raise the risk of new diabetes, about 9% in relative terms, mostly in people already near the threshold [22]. PCSK9 inhibitors and very low LDL-C have not shown a comparable increase [2, 17].
  • The adrenal glands and gonads can make their own cholesterol and also take it up from circulating lipoproteínas, and large PCSK9 programs have not shown a clinically important hormonal signal.

Achieved-LDL analyses are observational within trials and subject to selection and confusão residual; any isolated nominal findings are hypothesis-generating, and very long-term safety at extreme levels remains incompletely characterized.

Drug side effects are a separate matter: PCSK9 antibodies cause slightly more injection-site reactions (2.1% vs 1.6% in FOURIER) [2], and statins can cause muscle symptoms, though true muscle injury is rare. Randomized safety data for PCSK9 antibodies cover about two to three years; open-label exposure reached about 8.4 years [14]. In selected FOURIER extension participants, very low achieved LDL-C was not associated with a detected increase in several prespecified safety outcomes over the parent trial and its open-label extension [18]. That is reassuring but limited by participant selection, observational comparisons, and the inability to exclude rare or lifelong effects. Unlimited lifelong safety at extremely low levels has not been, and cannot yet be, established.

What Guidelines Recommend

Guidelines turn many trials into practical goals. The 2026 U.S. multisociety dislipidemia guideline reintroduced explicit LDL-C goals and divides people with atherosclerotic doença cardiovascular (ASCVD) into two groups [23]. Very-high-risk ASCVD means multiple major ASCVD events, or one major event plus multiple high-risk conditions; a recent heart attack alone does not automatically qualify.

Who What the 2026 U.S. guideline recommends
ASCVD, not very high risk High-intensity statin; LDL-C below 70 mg/dL and non-HDL-C below 100 mg/dL (recommended)
ASCVD, not very high risk Add ezetimibe, a PCSK9 antibody, or ácido bempedoico if needed to reach below 70 mg/dL
ASCVD, not very high risk Going further, to below 55 mg/dL (non-HDL-C below 85) (reasonable)
Very-high-risk ASCVD High-intensity statin; LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL (recommended)
Very-high-risk ASCVD Add ezetimibe and/or a PCSK9 antibody if needed to reach those goals
Very-high-risk ASCVD Bempedoic acid is a further add-on option

“Recommended” and “reasonable” are shown only for the LDL-C and non-HDL-C goals, where they follow the guideline’s own wording for stronger and moderate recommendations. For add-on drugs, the guideline’s recommendation tables give the formal classes, evidence levels, and eligibility criteria, and separate recommendations apply in special situations such as hipercolesterolemia grave [23].

The 2025 U.S. acute coronary syndrome guideline recommends high-intensity statin therapy and timely addition of nonstatin therapy for those above recommended levels [51]. European guidance after a heart attack recommends at least a 50% reduction and LDL-C below 55 mg/dL [52], and allows a goal below 40 mg/dL after a second vascular event within two years [53]. None of these specific targets was directly tested against another in a randomized target trial; they are expert judgments built on the evidence above.

Should a Second Drug Start in the Hospital?

AMUNDSEN randomized 2,161 heart attack patients and demonstrated that a strategy of giving the first evolocumab injection before PCI substantially improved attainment of the combined LDL-C target at 12 months (82% versus 40%). However, the difference in the trial’s main clinical end point (tested second in the prespecified order, after the LDL-C target), death or unplanned cardiovascular hospitalization, was not statistically significant at one year (14.6% versus 15.4%; adjusted OR 0.94, 95% CI 0.73–1.19). The trial therefore supports faster, more reliable target attainment, but does not demonstrate an additional short-term clinical-event benefit from this initiation strategy [24]. Standard care permitted a PCSK9 inhibitor when indicated, but only 3.8% of the standard-care group received one. The trial was powered (80%) to detect an odds ratio of 0.68 for this end point, so it argues against a large early clinical effect of starting a PCSK9 inhibitor in the catheterization laboratory; it does not exclude a smaller benefit or one that emerges with longer treatment. A prespecified per-protocol analysis suggested fewer events with evolocumab (10.2% versus 14.3%), but the investigators caution that this is likely affected by selection bias. A one-year result does not refute the longer outcome trials. EVOLVE-MI, testing evolocumab within 10 days of a heart attack, had not reported by the search cutoff. For now, early combination therapy is comprovado to reach lower LDL-C sooner and, in PACMAN-AMI, to improve one-year plaque changes; it is not yet proven to prevent more events than adding the same drug weeks later.

Where ApoB Fits

The guideline gives ApoB a role in assessing risco residual. ApoB is most useful when it and LDL-C disagree, as in people with high triglycerides, diabetes, or obesity, where LDL-C can look “at goal” while particle number remains high. No randomized trial reviewed here has compared ApoB treatment targets with LDL-C targets, so ApoB is best used as an added measure of remaining carga de partículas rather than as a proven separate target.

O resultado final

If someone has already had a heart attack, how much can intensive hipolipemiante change the disease and lower the chance of another event?

The disease: Within about a year, lowering LDL-C to roughly 25 to 30 mg/dL produces about twice the cap thickening seen with a statin alone, reduces imaging markers of lipid in untreated plaques, and adds roughly a 1.2 to 1.7 percentage-point reduction in percent atheroma volume compared with control groups. The plaque does not disappear, calcium does not dissolve, and the artery is not restored to normal.

The risk: In randomized trials after an acute coronary syndrome, relative reductions in each trial’s main composite endpoint were roughly 15%, with absolute benefits that differ by trial and follow-up. Across the pooled statin trials, each 38.7 mg/dL of LDL-C lowering reduced major vascular events by about 22%. Heart attacks and ischemic strokes are clearly reduced; a reduction in death is proven for statins in pooled analyses, but for add-on therapies only in nominal or open-label analyses.

How low can risk go: The studies reviewed have not identified a clear lower threshold, evidence becomes sparse at extreme LDL-C, and achieved-level analyses cannot define the optimal target; but events still occur even at extremely low LDL-C. People with lifelong low LDL-C have far less coronary disease, which points to duration of exposure as a major lever, but reductions in ischemic stroke and total mortality were not consistently shown. No evidence shows that cardiovascular events can be driven to zero.

Well established Sugestivo Still unresolved
Lowering LDL-C after a heart attack reduces repeat heart attack, ischemic stroke, and procedures, in proportion to the LDL reduction Benefit and safety at sustained LDL-C below 20 and even below 10 mg/dL Whether starting a PCSK9 inhibitor in the hospital prevents more events than starting it weeks later
The benefit continues below 70 and 55 mg/dL in randomized comparisons A lasting legacy benefit from earlier treatment (open-label, selected survivors) Whether any target below 55 mg/dL beats another in a randomized trial
Intensive LDL lowering improves plaque composition and modestly reduces plaque volume over about a year Far greater protection from lifelong low LDL-C The true floor of risk with lifelong near-zero LDL-C
For statins, ezetimibe, and PCSK9 antibodies, benefits generally outweigh recognized harms in the populations studied A cardiovascular-mortality benefit from adding PCSK9 inhibition Lifelong safety at extremely low LDL-C
That plaque changes explain part of the benefit; that ApoB and Lp(a) modify the plaque response How to prevent heart attacks caused by erosion; whether imaging-guided therapy helps

Practical Points to Discuss With Your Cardiologist

  • Start or continue high-intensity statin therapy during the hospital stay after an acute coronary syndrome, unless it is contraindicated or not tolerated.
  • Know your numbers and your risk category. The 2026 U.S. guideline recommends an LDL-C goal below 55 mg/dL for people with ASCVD classified as very high risk and below 70 mg/dL for those who are not, with a goal below 55 mg/dL reasonable in selected patients who are not at very high risk; European ACS guidance generally recommends at least a 50% reduction and LDL-C below 55 mg/dL after an acute coronary syndrome. Ask your clinician which category you are in and what your goal is. If you are not at goal on a statin, ask about adding ezetimibe or a PCSK9 inhibitor.
  • Ask for a one-time Lp(a) test, and consider ApoB, especially if your triglycerides are high or you have diabetes.
  • Do not read a rising calcium score as failure on its own. Discuss what it means in your case.
  • Treat the whole picture. Stop smoking, control blood pressure and glicemia, attend reabilitação cardíaca, and take prescribed terapia antiplaquetária.
  • Stay on therapy. LDL-C rises when treatment stops, and the benefit depends on how long it stays low.

Aviso médico: This article is for educational purposes and summarizes published research. It is not medical advice and does not replace individualized care from your physician. Do not start, stop, or change any medication without talking to your doctor.

Technical Appendix

About This Review

Este revisão narrativa selectively summarizes landmark peer-reviewed studies available through October 2026 and is not a revisão sistemática or meta-analysis. Where full text was not available, I used the peer-reviewed abstract only when it contained enough detail to support the specific statement. Press releases, registry pages, and news coverage were not used as evidence. Numbers not supported by the sources consulted were excluded. Every value plotted in a data figure was checked against the published abstract or primary report, as listed in the companion figure register; supplementary tables were not used. The bibliographic details of all 54 references (authors, title, journal, year, volume, and pages) were checked against the Crossref registry.

A1. HUYGENS Results

HUYGENS measure (change over about one year) Evolocumab + estatina Placebo + statin Difference* P value
Achieved LDL-C, mg/dL 28.1 87.2 about −59 <0,001
Minimum fibrous cap thickness, μm (primary endpoint) +42.7 +21.5 +21.2 0.015
Maximum lipid arc, degrees (secondary) −57.5 −31.4 −26.1 0.04
Macrophage index, mm (exploratory) −3.17 −1.45 −1.72 0.04
Percent atheroma volume, percentage points (IVUS subset; exploratory) −2.29 −0.61 −1.68 0.009
Microchannels and calcium (exploratory) Nenhuma diferença significativa NS

*Values and P values are as reported in the published HUYGENS abstract; 135 treated patients had evaluable imaging at follow-up. The cap-thickness values are least-squares means from the trial’s analysis of covariance in the full analysis set of 161 treated patients, 119 with paired OCT (registry results: difference 21.2 μm, 95% CI 4.7–37.7); IVUS values come from a smaller subset. Other differences are simple arithmetic on the reported group means; the P values come from the trial’s own models. Source: [1].

The protocol prespecified the absolute change in minimum cap thickness as the primary endpoint; secondary endpoints were the percent change in minimum cap thickness, the change in average minimum cap thickness, and the change in maximum lipid arc; IVUS plaque burden, macrophages, and microchannels were exploratory. The trial planned about 150 patients so that 125 would complete paired imaging, with 90% power to detect a 51 μm benefit; the observed adjusted benefit, 21.2 μm, was less than half that assumption yet still statistically significant [9]. Imaging trials can only measure patients who survive, stay in the study, and undergo a second catheterization with usable images, so missing follow-up imaging can introduce selection bias.

A2. HUYGENS Subgroup Analyses

These small, post hoc findings are hypothesis-generating and do not establish separate treatment thresholds or independently causal mechanisms. They were based on subsets and not adjusted for multiple comparisons.

  • Lipoproteína(a). In HUYGENS, the difference in cap thickening between evolocumab and placebo appeared larger in patients with high Lp(a) than in those with lower Lp(a), partly because the placebo-plus-statin group with high Lp(a) showed a smaller response [28]. Evolocumab lowered Lp(a) only modestly, and the analysis does not show that lowering Lp(a) caused the benefit. In PACMAN-AMI, baseline Lp(a) did not modify the plaque-volume or cap-thickness response to alirocumab, although patients with the highest Lp(a) had a smaller reduction in the plaque lipid signal [54].
  • Patients who reached lower ApoB levels showed more favorable OCT findings than those who did not [29]. Achieved ApoB was not randomized, and the full adjustment model could not be examined, so this does not establish an optimal ApoB target or an independent causal effect.
  • Achieved LDL-C. Pooling both arms, lower achieved LDL-C and larger LDL-C reductions were associated with greater cap thickening [1]; also non-randomized.

A3. Plaque-Imaging Trials

Avaliação População Treatment vs comparator Achieved LDL-C, mg/dL (mmol/L) Imaging, duration Main plaque finding Key limitations
HUYGENS (2022) [1] 161 post-NSTEMI Evolocumab vs placebo, both + statin 28.1 vs 87.2 (0.73 vs 2.25) OCT; IVUS subset; 50 wk Cap +42.7 vs +21.5 μm; lipid arc −57.5° vs −31.4°; PAV −2.29 vs −0.61 135 with evaluable follow-up imaging; denominators vary by endpoint; selected plaque
PACMAN-AMI (2022) [7] 300 acute MI, started <24 h after PCI Alirocumab vs placebo, both + rosuvastatin 20 23.6 vs 74.4 (0.61 vs 1.92) IVUS + NIRS + OCT; 52 wk PAV diff −1.21; LCBI diff −41.24; cap diff +29.65 μm 265 paired IVUS; 81% men
GLAGOV (2016) [30] 968 stable CAD on statin Evolocumab vs placebo 36.6 vs 93.0 (0.95 vs 2.41) IVUS; 76 wk treatment, week-78 IVUS PAV −0.95 vs +0.05; regression 64% vs 47% Not post-MI; composition substudy neutral
REVERSAL (2004) [32] 654 stable CAD Atorvastatin 80 vs pravastatina 40 79 vs 110 (2.0 vs 2.8) IVUS; 18 mo Progression halted vs continued Moderate LDL levels
ASTEROID (2006) [33] 507 CAD Rosuvastatin 40, single arm 60.8 (1.57) IVUS; 24 mo PAV −0.98 No control; attrition
SATURN (2011) [34] 1,385 CAD randomized; 1,039 with follow-up IVUS Rosuvastatin 40 vs atorvastatin 80 62.6 vs 70.2 (1.62 vs 1.82) IVUS; 104 wk Median PAV −1.22 vs −0.99 (P=0.17) No significant difference between the two statins; both regressed; no placebo arm
PRECISE-IVUS (2015) [35] 246 after PCI, Japan Atorvastatin + ezetimibe vs atorvastatin 63.2 vs 73.3 (1.63 vs 1.90) IVUS; 9–12 mo PAV −1.4 vs −0.3; regression 78% vs 58% Open label
EASY-FIT (2014) [36] 70 unstable angina Atorvastatin 20 vs 5 69 vs 78 (1.78 vs 2.02) OCT; 12 mo Cap +69% vs +17% Small; low-dose comparator
ODYSSEY J-IVUS (2019) [39] 206 recent ACS, Japan Alirocumab vs standard care Not shown IVUS; 36 wk No significant difference in primary plaque endpoint Neutral; short duration
YELLOW III (2026) [37] 110 stable CAD, lipid-rich plaque Evolocumab + statin, single arm Not reported in sources reviewed OCT + NIRS-IVUS; 26 wk Cap 70.9 → 97.7 μm; maxLCBI4mm 306.8 → 213.1; PAV −1.38 points No control group
CCTA/PET study (2025) [38] 47 stable, noncalcified plaque Evolocumab, single arm Not reported in sources reviewed CCTA + PET; 18 mo Noncalcified plaque fell; calcified plaque rose No control group

 

Values are not directly comparable across trials. PACMAN-AMI “diff” values are model-based between-group differences; other entries are within-arm changes as reported. PAV, percent atheroma volume; TAV, total atheroma volume; LCBI, núcleo lipídico burden index.

A4. Major Outcome Trials in Detail

Avaliação Population, timing, follow-up Treatment vs comparator LDL-C, mg/dL (baseline; achieved) Primary endpoint Resultado Mortality
MIRACL (2001) [43] 3,086 unstable angina or non-Q-wave MI; 24–96 h; 16 wk Atorvastatin 80 vs placebo ~124; 72 vs 135 at 16 wk Death, MI, resuscitated arrest, or recurrent isquemia with rehospitalization 14.8% vs 17.4%; RR 0.84 (0.70–1.00) No significant reduction in death or MI; benefit driven mainly by fewer rehospitalizations for symptomatic ischemia
PROVE IT–TIMI 22 (2004) [10] 4,162 ACS; within 10 days; mean 24 mo Atorvastatin 80 vs pravastatin 40 106; 62 vs 95 Death, MI, UA rehospitalization, revascularization, or stroke 22.4% vs 26.3%; 16% reduction (5%–26%) Death 2.2% vs 3.2%; P=0.07
IMPROVE-IT (2015) [4] 18,144 ACS; within 10 days; median ~6 y Simvastatin + ezetimibe vs simvastatin 93.8; 53.7 vs 69.5 CV death, major coronary event, or nonfatal stroke 32.7% vs 34.7% at 7 y; HR 0.936 (0.89–0.99) No difference
ODYSSEY OUTCOMES (2018) [3] 18,924 ACS 1–12 mo earlier; median 2.8 y Alirocumab vs placebo + statin ~92 (mean); ~40 vs ~93 at 4 mo CHD death, MI, ischemic stroke, or UA hospitalization 9.5% vs 11.1%; HR 0.85 (0.78–0.93) All-cause death 3.5% vs 4.1%, nominal only
FOURIER (2017) [2] 27,564 stable ASCVD; median 2.2 y Evolocumab vs placebo + statin 92 (median); 30 with evolocumab at 48 wk, 56 mg/dL lower than placebo CV death, MI, stroke, UA hospitalization, or revascularization 9.8% vs 11.3%; HR 0.85 (0.79–0.92) CV death HR 1.05 (0.88–1.25)
FOURIER-OLE (2022) [14] 6,635 FOURIER completers; median 5 more years Original evolocumab vs original placebo, all on open-label drug Median ~30 at extension week 12, on open-label evolocumab Same as FOURIER 3.36 vs 3.96 per 100 person-years; HR 0.85 (0.75–0.96) CV death 0.68 vs 0.90 per 100 person-years, HR 0.77 (0.60–0.99); exploratory
AMUNDSEN (2026) [24] 2,161 STEMI/NSTEMI (1,087 vs 1,074); open label; 12 mo Evolocumab before PCI + standard care vs standard care (PCSK9 inhibitor permitted; used in 3.8%) Median 16 vs 56 at 6 wk LDL-C <55 and ≥50% reduction; main clinical end point tested second in a prespecified hierarchy (80% power for OR 0.68) 792/970 (82%) vs 370/934 (40%); aOR 5.54 (4.50–6.82). Clinical composite 159/1,087 (14.6%) vs 165/1,074 (15.4%); aOR 0.94 (0.73–1.19) Not significant

Event rates are Kaplan–Meier estimates for PROVE IT–TIMI 22 and IMPROVE-IT and observed proportions for the others. Endpoints, populations, and follow-up differ, so these figures should not be compared across trials. AMUNDSEN was checked against the full primary JAMA article. CV, cardiovascular; CHD, coronary heart disease; UA, unstable angina.

Endpoint (treatment vs control) IMPROVE-IT (7 y) [4] ODYSSEY OUTCOMES (median 2.8 y) [3] FOURIER (median 2.2 y) [2]
Infarto do miocárdio 13.1% vs 14.8% 6.6% vs 7.6% 3.4% vs 4.6% (HR 0.73)
Stroke (trial-specific definition) Ischemic stroke 3.4% vs 4.1% Ischemic stroke 1.2% vs 1.6% Any stroke 1.5% vs 1.9% (HR 0.79)
Coronary revascularization 21.8% vs 23.4% (not significant) Ischemia-driven, lower with alirocumab 5.5% vs 7.0% (HR 0.78)
Cardiovascular death Nenhuma diferença significativa Not significant (HR 0.88) No difference (HR 1.05)
Mortalidade por todas as causas Nenhuma diferença significativa 3.5% vs 4.1% (HR 0.85), nominal only No difference

 

These components are secondary or nominal analyses, not multiplicity-controlled results.

A5. Limitations of the Evidence

  • Small imaging trials. HUYGENS randomized 161 patients, 135 of whom had evaluable follow-up imaging; PACMAN-AMI randomized 300, with 265 having paired IVUS. Both selected particular segments, had missing follow-up imaging, and enrolled mostly men. HUYGENS selected patients with already vulnerable-looking plaque.
  • Imaging is not histology. OCT can mistake fibrous tissue for lipid, and macrophage signals are indirect.
  • Financiamento do setor. Amgen funded HUYGENS, GLAGOV, and FOURIER; Sanofi and Regeneron supported ODYSSEY OUTCOMES, and Sanofi, Regeneron, and Infraredx funded PACMAN-AMI; Merck funded IMPROVE-IT; AstraZeneca funded SATURN. The major outcome trials used blinded treatment and independent event adjudicação, which limits but does not eliminate the concern.
  • Different populations. The outcome trials differ in timing, background therapy, and endpoint definitions.
  • Achieved-LDL and open-label analyses are vulnerable to selection and confounding.
  • Genetic studies estimate lifelong effects of specific variants; their effect sizes cannot be transferred directly to drugs started in adulthood.
  • Abstract-level sources. The following were reviewed at the abstract or published-summary level rather than in full text: the HUYGENS primary report (supplemented by its registry results) and ApoB analysis, Cohen 2006 (PCSK9 variants), Peloso 2019 (APOB variants), Benn 2010 and Benn 2019 (PCSK9 R46L), and Ference 2012 (Mendelian randomização). These are also marked in the reference list.
  • Sources of figure data. Each data figure plots values reported in the study cited in its caption; conceptual and model figures are labeled as illustrative.
  • Review method. This narrative review is based on selected peer-reviewed studies and guidelines rather than a registered systematic search. Some findings were extracted from peer-reviewed abstracts or published summaries. Numbers not supported by the sources consulted were excluded. Figure values were checked against the published abstracts or primary reports listed in the companion figure register, and each statement in the text is supported by its cited source at the level indicated above (abstract or full text).

Referências

  1. Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction (HUYGENS). JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002. PubMed: https://pubmed.ncbi.nlm.nih.gov/35431172/
  2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease (FOURIER). N Engl J Med. 2017;376:1713-1722. doi:10.1056/NEJMoa1615664. PubMed: https://pubmed.ncbi.nlm.nih.gov/28304224/
  3. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379:2097-2107. doi:10.1056/NEJMoa1801174. PubMed: https://pubmed.ncbi.nlm.nih.gov/30403574/
  4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes (IMPROVE-IT). N Engl J Med. 2015;372:2387-2397. doi:10.1056/NEJMoa1410489. PubMed: https://pubmed.ncbi.nlm.nih.gov/26039521/
  5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272. doi:10.1056/NEJMoa054013 [abstract reviewed]
  6. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631-2639. doi:10.1016/j.jacc.2012.09.017 [abstract summary reviewed]
  7. Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327:1771-1781. doi:10.1001/jama.2022.5218
  8. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis (PROSPECT). N Engl J Med. 2011;364:226-235. doi:10.1056/NEJMoa1002358
  9. Nicholls SJ, Nissen SE, Prati F, et al. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther. 2021;11(1):120-129. doi:10.21037/cdt-20-684. PMCID: PMC7944215. PubMed: https://pubmed.ncbi.nlm.nih.gov/33708484/
  10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT–TIMI 22). N Engl J Med. 2004;350:1495-1504. doi:10.1056/NEJMoa040583. PubMed: https://pubmed.ncbi.nlm.nih.gov/15007110/
  11. Murphy SA, Pedersen TR, Gaciong ZA, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4:613-619. doi:10.1001/jamacardio.2019.0886
  12. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-1681. doi:10.1016/S0140-6736(10)61350-5. PubMed: https://pubmed.ncbi.nlm.nih.gov/21067804/
  13. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289-1297. doi:10.1001/jama.2016.13985
  14. O’Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease (FOURIER-OLE). Circulation. 2022;146:1109-1119. doi:10.1161/CIRCULATIONAHA.122.061620
  15. Hopewell JC, Malik R, Valdés-Márquez E, Worrall BB, Collins R; METASTROKE Collaboration of the ISGC. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke. Eur Heart J. 2018;39:354-359. doi:10.1093/eurheartj/ehx373
  16. Benn M, Tybjærg-Hansen A, Nordestgaard BG. Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality. J Am Coll Cardiol. 2019;73:3102-3114. doi:10.1016/j.jacc.2019.03.517 [abstract reviewed]
  17. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390:1962-1971. doi:10.1016/S0140-6736(17)32290-0
  18. Gaba P, O’Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147:1192-1203. doi:10.1161/CIRCULATIONAHA.122.063399
  19. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). N Engl J Med. 2017;377:1119-1131. doi:10.1056/NEJMoa1707914
  20. Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med. 2019;381:2497-2505. doi:10.1056/NEJMoa1912388
  21. Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab (EBBINGHAUS). N Engl J Med. 2017;377:633-643. doi:10.1056/NEJMoa1701131. PubMed: https://pubmed.ncbi.nlm.nih.gov/28813214/
  22. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-742. doi:10.1016/S0140-6736(09)61965-6
  23. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia. Circulation. 2026;153(17). doi:10.1161/CIR.0000000000001423. Copublished in J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016. PubMed: https://pubmed.ncbi.nlm.nih.gov/41824552/
  24. Montalescot G, Ferrari E, Souteyrand G, et al. LDL cholesterol lowering with evolocumab before percutaneous coronary intervention for acute myocardial infarction: the AMUNDSEN randomized clinical trial. JAMA. Published online August 29, 2026. doi:10.1001/jama.2026.17302. PubMed: https://pubmed.ncbi.nlm.nih.gov/42666092/
  25. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276-1282. doi:10.1056/NEJM199705013361802
  26. Jia H, Abtahian F, Aguirre AD, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62:1748-1758. doi:10.1016/j.jacc.2013.05.071
  27. Fujino M, Nicholls SJ. PCSK9 inhibitors and coronary atherosclerosis: insights from recent intravascular imaging clinical trials. Cardiometab Syndr J. 2023;3(2):103-109. doi:10.51789/cmsj.2023.3.e14
  28. Di Giovanni G, et al. Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis. Eur J Prev Cardiol. 2026;33(11):2047-2054. doi:10.1093/eurjpc/zwaf211
  29. Fujino M, et al. Achieved levels of apolipoprotein B and plaque composition after acute coronary syndromes: insights from HUYGENS. Atherosclerosis. 2025;403:119145. doi:10.1016/j.atherosclerosis.2025.119145 [abstract reviewed]
  30. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316:2373-2384. doi:10.1001/jama.2016.16951. PubMed: https://pubmed.ncbi.nlm.nih.gov/27846344/
  31. Nicholls SJ, et al. Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol. 2018;72:2012-2021. doi:10.1016/j.jacc.2018.06.078
  32. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial (REVERSAL). JAMA. 2004;291:1071-1080. doi:10.1001/jama.291.9.1071
  33. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565. doi:10.1001/jama.295.13.jpc60002
  34. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease (SATURN). N Engl J Med. 2011;365:2078-2087. doi:10.1056/NEJMoa1110874. PubMed: https://pubmed.ncbi.nlm.nih.gov/22085316/
  35. Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495-507. doi:10.1016/j.jacc.2015.05.065. PubMed: https://pubmed.ncbi.nlm.nih.gov/26227186/
  36. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64:2207-2217. doi:10.1016/j.jacc.2014.08.045
  37. Kini AS, Vengrenyuk Y, Liu J, et al. Intracoronary imaging and transcriptomic characteristics before and after maximum lipid-lowering therapy: YELLOW-III study of evolocumab and maximum statin therapy in chronic coronary disease. JACC Cardiovasc Imaging. 2026;19(4):516-534. doi:10.1016/j.jcmg.2025.12.013. PubMed: https://pubmed.ncbi.nlm.nih.gov/41758107/
  38. Han D, et al. Effects of evolocumab on coronary plaque composition and microcalcification activity by coronary PET and CT angiography. JACC Cardiovasc Imaging. 2025;18:589-599. doi:10.1016/j.jcmg.2025.01.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/40178463/
  39. Ako J, Hibi K, Tsujita K, et al. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome: the ODYSSEY J-IVUS trial. Circ J. 2019;83(10):2025-2033. doi:10.1253/circj.CJ-19-0412
  40. Prati F, Romagnoli E, Gatto L, et al. Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study. Eur Heart J. 2020;41:383-391. doi:10.1093/eurheartj/ehz520
  41. Puri R, Nicholls SJ, Shao M, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol. 2015;65:1273-1282. doi:10.1016/j.jacc.2015.01.036
  42. Lee SE, Chang HJ, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging. 2018;11:1475-1484. doi:10.1016/j.jcmg.2018.04.015
  43. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA. 2001;285:1711-1718. doi:10.1001/jama.285.13.1711. PubMed: https://pubmed.ncbi.nlm.nih.gov/11277825/
  44. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-2472. doi:10.1093/eurheartj/ehx144
  45. Schwartz GG, Szarek M, Bittner VA, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023;44:1408-1417. doi:10.1093/eurheartj/ehad144. PubMed: https://pubmed.ncbi.nlm.nih.gov/36879424/
  46. Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med. 2020;383:1838-1847. doi:10.1056/NEJMoa2021372
  47. Peloso GM, Nomura A, Khera AV, et al. Rare protein-truncating variants in APOB, lower low-density lipoprotein cholesterol, and protection against coronary heart disease. Circ Genom Precis Med. 2019;12:e002376. doi:10.1161/CIRCGEN.118.002376 [abstract reviewed]
  48. Benn M, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol. 2010;55:2833-2842. doi:10.1016/j.jacc.2010.02.044 [abstract reviewed]
  49. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514-523. doi:10.1086/507488. PMCID: PMC1559532
  50. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack (SPARCL). N Engl J Med. 2006;355:549-559. doi:10.1056/NEJMoa061894
  51. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes. J Am Coll Cardiol. 2025;85:2135-2237. doi:10.1016/j.jacc.2024.11.009. PubMed: https://pubmed.ncbi.nlm.nih.gov/40013746/
  52. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. 2024;13:55-161. doi:10.1093/ehjacc/zuad107. PubMed: https://pubmed.ncbi.nlm.nih.gov/37740496/
  53. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. doi:10.1016/j.atherosclerosis.2019.08.014. PubMed: https://pubmed.ncbi.nlm.nih.gov/31591002/
  54. Koskinas KC, Häner J, Ueki Y, et al. Association of lipoprotein(a) with changes in coronary atherosclerosis in patients treated with alirocumab. Circ Cardiovasc Imaging. 2024;17:e016683. doi:10.1161/CIRCIMAGING.124.016683. PubMed: https://pubmed.ncbi.nlm.nih.gov/39561225/

Nota de Transparência: Este artigo foi elaborado com o auxílio de ferramentas de IA. O conteúdo final foi cuidadosamente revisado e editado pelo autor, que é responsável por sua precisão. Este site é mantido por um Conselho Consultivo de pesquisadores. Todo o conteúdo tem fins exclusivamente educacionais e não constitui orientação médica.

Declaração de Transparência Editorial e de IA

Compartilhar esta publicação

Artigos Relacionados

Assistir no YouTube

Receba notificações sobre novos artigos!

Aplicativo de IA

Calculadora de Risco Cardíaco

Calculadora de risco cardíaco com histórico familiar educacional, com insights do escore H, entrada visual de árvore genealógica e relatórios em PDF compartilháveis.

Leia por que este aplicativo é tão importante aqui.